Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors
Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.
Bristol Myers Squibb (BMY) is a pharmaceutical company with roots dating back to 1858 and 1887. It has consistently demonstrated its ability to thrive in the highly competitive and innovative pharmaceutical industry, making it an important consideration for investors currently analyzing the impending patent expiration for their cardiovascular drug Eliquis in 2028. While patent expirations are a common occurrence in the drug business and a significant revenue hit for BMY, they are an expected part of the business landscape.
Recently, there has been a buzz around Bristol Myers Squibb regarding a potential acquisition by AstraZeneca (AZN). However, this rumor appears to be overstated, as industry experts do not foresee a high likelihood of such a merger taking place. In the larger context of investing, focusing on short-term mergers and acquisitions may not be the most prudent long-term strategy.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
